Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer
Public ClinicalTrials.gov record NCT02217709. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Trial of Phenelzine in Non-metastatic Recurrent Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies phenelzine sulfate in treating patients with prostate cancer that has not spread to other parts of the body and has come back. Phenelzine sulfate is a type of antidepressant that works by decreasing the amount of a protein called monoamine oxidase (MAO). MAO drugs may have an anticancer effect in prostate cancer.
Study identification
- NCT ID
- NCT02217709
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 26 participants
Conditions and interventions
Conditions
Interventions
- phenelzine sulfate Drug
- laboratory biomarker analysis Other
- questionnaire administration Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 7, 2014
- Primary completion
- Jun 28, 2020
- Completion
- Jun 28, 2020
- Last update posted
- Jun 24, 2026
2014 – 2020
United States locations
- U.S. sites
- 4
- U.S. states
- 1
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC Norris Westside Cancer Center | Beverly Hills | California | 90211 | — |
| Los Angeles County-USC Medical Center | Los Angeles | California | 90033 | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Keck Medical Center of USC Pasadena | Pasadena | California | 91105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Adenocarcinoma of the Prostate trials
Other public records listing Adenocarcinoma of the Prostate. Sorted by last update posted; newest first. Not a recommendation.
- NCT03624660: Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer Active, not recruiting
- NCT07650240: Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial Not yet recruiting
- NCT02296229: Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer Active, not recruiting
- NCT03511196: Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Active, not recruiting
- NCT02023463: Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer Active, not recruiting
- NCT01655836: High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02217709, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 24, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02217709 live on ClinicalTrials.gov.